Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.7 EUR | -0.45% | -4.39% | +2.17% |
03-07 | Neurones: 11% growth in annual net income | CF |
03-06 | Neurones S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 459 | 500.3 | 566.7 | 920.3 | 950.8 | 1,085 | 1,085 |
Enterprise Value (EV) 1 | 284.5 | 282 | 334 | 655.7 | 679 | 1,062 | 790.8 |
P/E ratio | 17.7 x | 16.2 x | 18.4 x | 24.5 x | 21.6 x | 21.6 x | 19.9 x |
Yield | 0.32% | 0.97% | 0.85% | 2.63% | 2.55% | 2.57% | 2.68% |
Capitalization / Revenue | 0.94 x | 0.98 x | 1.08 x | 1.59 x | 1.43 x | 1.43 x | 1.37 x |
EV / Revenue | 0.58 x | 0.55 x | 0.64 x | 1.13 x | 1.02 x | 1.43 x | 1 x |
EV / EBITDA | 5.3 x | 4.56 x | 5.57 x | 8.6 x | 7.59 x | 11.5 x | 8.08 x |
EV / FCF | 11 x | 6 x | 5.56 x | 12.9 x | 15.3 x | 20.6 x | - |
FCF Yield | 9.07% | 16.7% | 18% | 7.74% | 6.53% | 4.86% | - |
Price to Book | 1.72 x | 1.68 x | 1.76 x | 2.95 x | 2.87 x | 3.04 x | 2.84 x |
Nbr of stocks (in thousands) | 24,286 | 24,286 | 24,218 | 24,218 | 24,224 | 24,272 | 24,272 |
Reference price 2 | 18.90 | 20.60 | 23.40 | 38.00 | 39.25 | 44.70 | 44.70 |
Announcement Date | 19-03-13 | 20-03-04 | 21-02-10 | 22-02-09 | 23-02-08 | 24-03-06 | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales 1 | 490.1 | 510.1 | 524.5 | 579.9 | 665.4 | 741.2 | 793.1 |
EBITDA 1 | 53.69 | 61.79 | 60 | 76.28 | 89.44 | 92.61 | 97.91 |
EBIT 1 | 46 | 53.7 | 51.9 | 61.6 | 72.9 | 75.9 | 79.39 |
Operating Margin | 9.39% | 10.53% | 9.9% | 10.62% | 10.96% | 10.24% | 10.01% |
Earnings before Tax (EBT) 1 | 44 | 53.8 | 53.6 | 61.7 | 72.86 | 80.76 | - |
Net income 1 | 26 | 30.8 | 30.9 | 37.7 | 44.3 | 49.4 | 54.57 |
Net margin | 5.31% | 6.04% | 5.89% | 6.5% | 6.66% | 6.66% | 6.88% |
EPS 2 | 1.070 | 1.270 | 1.270 | 1.550 | 1.820 | 2.030 | 2.247 |
Free Cash Flow 1 | 25.8 | 47 | 60.1 | 50.76 | 44.36 | 51.6 | - |
FCF margin | 5.26% | 9.21% | 11.46% | 8.75% | 6.67% | 6.96% | - |
FCF Conversion (EBITDA) | 48.06% | 76.06% | 100.16% | 66.55% | 49.6% | 55.72% | - |
FCF Conversion (Net income) | 99.23% | 152.6% | 194.49% | 134.65% | 100.14% | 104.45% | - |
Dividend per Share 2 | 0.0600 | 0.2000 | 0.2000 | 1.000 | 1.000 | 1.150 | 1.200 |
Announcement Date | 19-03-13 | 20-03-04 | 21-02-10 | 22-02-09 | 23-02-08 | 24-03-06 | - |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | 175 | 218 | 233 | 265 | 272 | 258 | 294 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | 25.8 | 47 | 60.1 | 50.8 | 44.4 | 51.6 | - |
ROE (net income / shareholders' equity) | 10.2% | 11.4% | 9.97% | 11.9% | 13.8% | 15.3% | 14.8% |
ROA (Net income/ Total Assets) | - | - | - | - | 7.47% | - | - |
Assets 1 | - | - | - | - | 593.3 | - | - |
Book Value Per Share 2 | 11.00 | 12.20 | 13.30 | 12.90 | 13.70 | 14.70 | 15.80 |
Cash Flow per Share 2 | 1.280 | 2.520 | 2.770 | 2.360 | 2.660 | 2.970 | 3.050 |
Capex | 6.95 | 7.89 | - | - | 10.6 | - | - |
Capex / Sales | 1.42% | 1.55% | - | - | 1.59% | - | - |
Announcement Date | 19-03-13 | 20-03-04 | 21-02-10 | 22-02-09 | 23-02-08 | 24-03-06 | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.17% | 1.16B | |
-12.23% | 194B | |
+0.74% | 166B | |
+2.19% | 153B | |
+4.34% | 99.85B | |
+7.04% | 77.56B | |
+19.09% | 73.55B | |
-7.30% | 71B | |
-20.54% | 52.81B | |
+0.53% | 47.86B |
- Stock Market
- Equities
- NRO Stock
- Financials NEURONES